0001213900-23-070101.txt : 20230925 0001213900-23-070101.hdr.sgml : 20230925 20230823082226 ACCESSION NUMBER: 0001213900-23-070101 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230823 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BiondVax Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 CORRESP 1 filename1.htm

BiondVax Pharmaceuticals Ltd.

Jerusalem BioPark, 2^nd Floor

Kiryat Hadassah, Building 1, JBP

Jerusalem, Israel 9112001

August 23, 2023

VIA EDGAR

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Attention: Ms. Cindy Polynice

Re:

REQUEST FOR ACCELERATION OF EFFECTIVENESS
BiondVax Pharmaceuticals Ltd. (CIK No. 0001611747)
Registration Statement on Form F-3 (File No. 333-274078)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, BiondVax Pharmaceuticals Ltd. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form F-3 (File No. 333-274078) so that it will be declared effective at 10:00 a.m., Eastern Standard Time, on August 25, 2023, or as soon thereafter as is practicable.

Should you have any questions regarding this letter, please do not hesitate to contact Perry Wildes, Adv., at +972 (3) 607-4444 or perry@gkh-law.com, of Goldfarb Gross Seligman & Co., counsel to the Company.

	Sincerely,

	BIONDVAX PHARMACEUTICALS LTD.

	By:	/s/ Amir Reichman
		Amir Reichman
		Chief Executive Officer